Home  /  Resource Library  /  Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Results of a phase II clinical trial involving rituximab and bendamustine for first line treatment of Mucosa Associated Lymphoid Tissue (MALT) lymphoma.